A novel combination of paclitaxel, etoposide, and cyclophosphamide for stem cell mobilization and tumor cytoreduction in ovarian cancer.
Bilgrami
S
S
Feingold
J M
JM
Kapur
D
D
Bona
R D
RD
Edwards
R L
RL
Khan
A M
AM
Rodriguez-Pinero
F
F
Tutschka
P J
PJ
D000505:Alopecia / Q000209:etiology; D018952:Antigens, CD34 / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D001772:Blood Cell Count; D001803:Blood Transfusion; D002291:Carcinoma, Papillary / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000633:toxicity; D016889:Endometrial Neoplasms / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D005047:Etoposide / Q000008:administration & dosage / Q000633:toxicity; D005260:Female; D005334:Fever / Q000209:etiology; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007710:Klebsiella Infections / Q000209:etiology; D007937:Leukapheresis; D008875:Middle Aged; D009503:Neutropenia / Q000209:etiology; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000633:toxicity; D012704:Serous Membrane / Q000473:pathology; D043823:Taxoids
D018952:Antigens, CD34; D043823:Taxoids; D005047:Etoposide; D003520:Cyclophosphamide; D017239:Paclitaxel